Tempest Therapeutics
TPST
61 hedge funds and large institutions have $66.6M invested in Tempest Therapeutics in 2020 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 22 increasing their positions, 13 reducing their positions, and 4 closing their positions.
275% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 4
69% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 13
22% more funds holding
Funds holding: 50 → 61 (+11)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
18% less capital invested
Capital invested by funds: $81.3M → $66.6M (-$14.6M)
85% less call options, than puts
Call options by funds: $2.03M | Put options by funds: $13.9M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$2.8M |
| 2 |
DM
Deerfield Management
New York
|
+$1.26M |
| 3 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$1.1M |
| 4 |
BlackRock
New York
|
+$789K |
| 5 |
CM
Caption Management
Oklahoma City,
Oklahoma
|
+$427K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ASP
Adams Street Partners
Chicago,
Illinois
|
-$1.71M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.34M |
| 3 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$945K |
| 4 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$873K |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$130K |
TPST Hedge Fund Activity: Q1 2020 in Review
61 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Tempest Therapeutics (TPST) for Q1 2020, worth a combined $66.6M — down 18% from $81.3M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new TPST positions and 4 closed out — a net gain of 11 holders — while 22 added to existing stakes and 13 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $2.8M. The largest seller was Adams Street Partners, cutting an estimated $1.71M.
- 61 institutional investors held Tempest Therapeutics (TPST) as of Q1 2020, up from 50 in Q4 2019.
- Funds reported $66.6M of Tempest Therapeutics stock for Q1 2020, down 18% quarter-over-quarter.
- 15 funds opened new Tempest Therapeutics positions in Q1 2020 and 4 closed out, a net change of +11 holders.
- The largest Tempest Therapeutics buyer in Q1 2020 was Citadel Advisors, an estimated $2.8M added.
- The largest Tempest Therapeutics seller in Q1 2020 was Adams Street Partners, an estimated $1.71M sold.
Based on aggregated 13F filings for Q1 2020.